Genotyping assay to predict CYP3A5 phenotype (SJ-01-0005)

St. Jude Reference #SJ-01-0005


CYP3A5 is an important contributor in drug clearance and involved in regulating the levels of endogenous paracrine or endocrine factors in certain organs such as the kidneys. Two single nucleotide polymorphisms found in CYP3A5 have been identified that result in splice variants, which contribute to decreased levels of CYP3A5 protein. A diagnostic assay detecting these mutations would be an important tool in identifying appropriate therapeutic treatments for individual patients.


Drug metabolism

Granted patents or published applications

U.S. Patent No. 7,022,475

Related scientific references

Givens R, et al., “CYP3A5 Genotype predicts activity and blood pressure in healthy adults” J Appl Physiol. Sep; 95(3):1297-1300;

Lin Y, et al. “Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism”, Mol Pharmacol. 62(1):162-72 (2002);

Lamba J et al., “Common allelic variants of cytochrome P4503A4 and their prevalence in different populations”, Pharmacogenetics. 12(2):121-32 (2002).

Licensing opportunities

We are currently seeking non-exclusive licensing opportunities in all fields for the development of this technology. Contact:

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.